Immunotherapy efficacy and gender: discovery in precision medicine

Affiliations

¹ Emory School of Medicine, Atlanta, GA, USA.
² Thoracic Oncology Department, Larrey Hospital, University Hospital of Toulouse, Toulouse, France.

Editorial

Bryan C Ulrich et al. Transl Lung Cancer Res. 2018 Sep.

. 2018 Sep;7(Suppl 3):S211-S213.

doi: 10.21037/tlcr.2018.08.05.

¹ Emory School of Medicine, Atlanta, GA, USA.
² Thoracic Oncology Department, Larrey Hospital, University Hospital of Toulouse, Toulouse, France.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis.
Conforti F, Pala L, Bagnardi V, De Pas T, Martinetti M, Viale G, Gelber RD, Goldhirsch A. Conforti F, et al. Lancet Oncol. 2018 Jun;19(6):737-746. doi: 10.1016/S1470-2045(18)30261-4. Epub 2018 May 16. Lancet Oncol. 2018. PMID: 29778737

1. FDA approves nivolumab plus ipilimumab combination for intermediate or poor-risk advanced renal cell carcinoma [Internet]. Fda.gov. 2018. Available online: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm604685.htm
1. Pembrolizumab (Keytruda) 5-10-17 [Internet]. Fda.gov. 2017. Available online: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm558048.htm
1. FDA grants regular approval to nivolumab for adjuvant treatment of melanoma [Internet]. Fda.gov. 2017. Available online: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm590004.htm
1. FDA grants accelerated approval to pembrolizumab for advanced gastric cancer [Internet]. Fda.gov. 2018. Available online: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm577093.htm
1. FDA approves pembrolizumab for advanced cervical cancer with disease progression during or after chemotherapy [Internet]. Fda.gov. 2018. Available online: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm610572.htm